Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Climb Bio, Inc. - Common Stock (NQ:CLYM)

14.60 +0.35 (+2.46%)
Streaming Delayed Price Updated: 2:03 PM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 524,501
Open 14.49
Bid (Size) 14.60 (200)
Ask (Size) 14.62 (200)
Prev. Close 14.25
Today's Range 14.30 - 14.96
52wk Range 1.540 - 18.33
Shares Outstanding 26,993,401
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug ↗
Climb Bio (NASDAQ:CLYM) presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing... 
Via MarketBeat
News headline image
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
From Climb Bio, Inc.
Via GlobeNewswire

Performance

YTD
+289.4%
+289.4%
1 Month
-10.6%
-10.6%
3 Month
+27.1%
+27.1%
6 Month
+104.8%
+104.8%
1 Year
+615.7%
+615.7%

More News

Read More
News headline image
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect ↗
Via MarketBeat
News headline image
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio, Inc. Announces $110.0 Million Private Placement
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Unusual volume stocks in Tuesday's session ↗
Via Chartmill
News headline image
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
From Climb Bio, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Climb Bio, Inc. - Common Stock publicly traded?
Yes, Climb Bio, Inc. - Common Stock is publicly traded.
What exchange does Climb Bio, Inc. - Common Stock trade on?
Climb Bio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Climb Bio, Inc. - Common Stock?
The ticker symbol for Climb Bio, Inc. - Common Stock is CLYM on the Nasdaq Stock Market
What is the current price of Climb Bio, Inc. - Common Stock?
The current price of Climb Bio, Inc. - Common Stock is 14.60
When was Climb Bio, Inc. - Common Stock last traded?
The last trade of Climb Bio, Inc. - Common Stock was at 09/14/26 02:03 PM ET
What is the market capitalization of Climb Bio, Inc. - Common Stock?
The market capitalization of Climb Bio, Inc. - Common Stock is 394.13M
How many shares of Climb Bio, Inc. - Common Stock are outstanding?
Climb Bio, Inc. - Common Stock has 394M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.